ArticleHuman vaccines & immunotherapeutics2025
The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of dissolving microneedle patches (dMNPs) for inactivated rotavirus vaccine (IRV) requires concurrent evaluation of safety parameters, including local and systemic toxicity and immune response characteristics. The aim of this study is to evaluate the toxicological safety profiles and immunogenic potential of IRV dMNPs in rats through assessment of systemic toxicity, local responses, and neutralizing activities. IRV dMNPs were examined for stability under different storage conditions (5 ± 3°C and 25 ± 2°C) for up to 24 months. Toxicology assessment included clinical observation, body weight monitoring, food consumption, hematology, clinical chemistry, organ weight analysis, and histopathological examination. Local tolerance was evaluated using Draize scoring and microscopic examination of the administration sites. Immunogenicity was evaluated by measuring neutralizing activities in sera against homotypic and heterotypic RV strains. The potency of IRV dMNPs was found stable for at least 24 months at 5 ± 3°C, and for 12 months at 25 ± 2°C. Toxicological evaluation showed no adverse systemic effects, with all clinical pathology parameters remaining within normal ranges. Local dermal reactions were mild (mean Draize scores <1.5) and subsided within 48 h. Histopathology showed only low to mild inflammatory changes at the application sites, with complete resolution by the end of study (day 57). Immunological analysis showed robust and cross-reactive neutralizing activities against homotypic and heterotypic RV strains in sera of rats. IRV dMNPs showed strong stability and an excellent safety profile while also inducing robust and extensive immune responses, supporting its further development as an alternate IRV platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.